Search

Harmony Biosciences Holdings Inc

Open

BrancheGesundheitswesen

40.46 -1.99

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

40.22

Max

42.1

Schlüsselkennzahlen

By Trading Economics

Einkommen

43M

75M

Verkäufe

46M

261M

KGV

Branchendurchschnitt

13.625

55.725

EPS

1.28

Gewinnspanne

28.87

Angestellte

293

EBITDA

53M

102M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+5.14% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

391M

2.5B

Vorheriger Eröffnungskurs

42.45

Vorheriger Schlusskurs

40.46

Nachrichtenstimmung

By Acuity

50%

50%

119 / 339 Ranking in Healthcare

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Sept. 2026, 19:45 UTC

Harmony Biosciences Holdings Inc shares fell sharply after an early gain, currently trading below Monday's close but above the 20-day moving average.

21. Sept. 2026, 21:10 UTC

Harmony Biosciences Holdings Inc is experiencing a significant decline in after-market trading, moving lower since Monday's close amid notable volatility.

18. Sept. 2026, 21:11 UTC

Harmony Biosciences Holdings Inc is experiencing a significant decline in after-market trading, moving lower from a minor peak shortly after Friday's close.

17. Sept. 2026, 23:16 UTC

Harmony Biosciences Holdings Inc saw a modest increase in after-market trading, positioned above its 20-day moving average and near its one-month range high.

16. Sept. 2026, 23:06 UTC

Event

Harmony Biosciences' WAKIX® receives approval from Japan's Ministry of Health for treating excessive daytime sleepiness, contributing to a modest after-market gain.

15. Sept. 2026, 21:01 UTC

Harmony Biosciences Holdings Inc shares are trading higher in after-market hours, reflecting strong momentum despite no specific company news.

14. Sept. 2026, 20:08 UTC

Harmony Biosciences is higher during Monday's session, reflecting broader market gains since Friday. The stock pulled back from an earlier session high.

11. Sept. 2026, 22:56 UTC

Harmony Biosciences Holdings Inc is trading higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

9. Sept. 2026, 20:07 UTC

Harmony Biosciences Holdings Inc shares are lower during Wednesday's session, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

8. Sept. 2026, 20:13 UTC

Harmony Biosciences Holdings Inc is higher in after-market trading, supported by solid performance above its 20-day moving average and nearing its one-month trading range.

3. Sept. 2026, 20:02 UTC

News
Event

Harmony Biosciences announced it will present EPX-100 data at a future congress. Shares are trading lower, reversing from an earlier session high.

2. Sept. 2026, 20:01 UTC

Harmony Biosciences Holdings Inc is higher today, reflecting positive market response despite no specific news. Broader market context includes slower job growth reported by ADP.

1. Sept. 2026, 23:01 UTC

Harmony Biosciences Holdings Inc shares are higher in after-market trading, continuing an upward trend from three consecutive sessions of gains. No specific news was identified.

31. Aug. 2026, 22:06 UTC

Harmony Biosciences shares are higher in after-market trading, rebounding from an initial dip amid geopolitical tensions affecting broader market conditions.

28. Aug. 2026, 20:07 UTC

Harmony Biosciences Holdings Inc shares are lower during Friday's session, continuing a decline since Thursday's close amid no specific news to explain the downturn.

27. Aug. 2026, 19:56 UTC

News

Harmony Biosciences will participate in the 2026 Cantor Global Healthcare Conference. Shares are higher today, reflecting positive market sentiment since Wednesday's close.

26. Aug. 2026, 20:08 UTC

News

Wolfe Research initiated coverage on Harmony Biosciences with an Outperform rating and a $60 price target, contributing to higher shares during Wednesday's session.

25. Aug. 2026, 19:26 UTC

Shares of Harmony Biosciences Holdings Inc. are modestly higher, trading within a narrow range amid routine performance during Tuesday's session.

24. Aug. 2026, 21:01 UTC

Harmony Biosciences Holdings Inc is trading higher in after-market hours, reflecting a broader rebound in the bond market as Treasury yields decline.

21. Aug. 2026, 22:31 UTC

Harmony Biosciences Holdings Inc. is trading higher in after-market hours, reaching the upper end of its one-month range and above the 20-day moving average.

20. Aug. 2026, 23:31 UTC

Harmony Biosciences Holdings Inc shares are higher in after-market trading, supported by strong momentum above the 20-day moving average and within its one-month range.

19. Aug. 2026, 19:56 UTC

Harmony Biosciences Holdings Inc. is trading higher, reaching a session high and remaining above its 20-day moving average during Wednesday's session.

14. Aug. 2026, 19:46 UTC

Harmony Biosciences shares are lower as the Pharmaceuticals sub-sector declines. The stock remains above its 20-day moving average, indicating some underlying strength.

13. Aug. 2026, 22:51 UTC

Harmony Biosciences shares are rising in after-market trading, supported by favorable macroeconomic indicators and a broader trend in major averages closing higher.

11. Aug. 2026, 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

10. Aug. 2026, 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

7. Aug. 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6. Aug. 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5. Aug. 2026, 20:03 UTC

Social Media
Event
News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4. Aug. 2026, 20:04 UTC

Social Media
News
Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

5.14% Vorteil

12-Monats-Prognose

Durchschnitt 43.667 USD  5.14%

Hoch 60 USD

Tief 30 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

4

Buy

4

Halten

1

Sell

Stimmung

By Acuity

119 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.